Insight

Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy

Photo from Tanja Obradovic/LinkedIn

May 20, 2024, 02:15

Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy

Tanja Obradovic shared on LinkedIn:

“Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy are certain to be raised even more after announcement today that Phase 3 KeyVibe-010 study will be discontinued due to futility.

Study tested Vibostolimab and Pembrolizumab co-formulation as an adjuvant treatment in resected high-risk melanoma patients vs Pembrolizumab monotherapy standard of care.

Patients did not tolerate well co-formulated mix and higher discontinuation rate in the co-formulation arm prevented achievement of statistical significance for the primary endpoint of recurrence-free survival (RFS).

Numerous large Pharma and Biotech companies have invested heavily in TIGIT clinical pipeline but results so far have been mixed with major updates still pending.”

For more read the recent review article.

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.

cancer Cancer research clinical oncology ICON PLCh inhibitor immunotherapy OncoDaily Oncology PD(L)-1 pembrolizumab Tanja Obradovic TIGIT inhibitors Vibostolimab

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage